Big pharma, Partnering, Pharma

Zealand Pharma partners Eli Lilly for peptide drug R&D

Posted on 30 August 2013

Tags: , , ,

Zealand Pharma announced an exclusive peptide drug research and development collaboration agreement with pharma partners Eli Lilly and Company.

Under the agreement, Zealand pharma partners Lilly in the design and development of potentially first-in-class peptide therapeutics for the treatment of Type 2 diabetes and obesity based on a novel approach discovered by Lilly.

The pharma partners will share in the funding, risk and reward of the program.

Future expansion between the pharma partners will lead to additional drug targets and disease areas is possible.

No financial terms of the agreement have been disclosed.

Related

Report: Partnering Deals and Alliances with Eli Lilly

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
a1banner300x150animgif